enGene Holdings Inc.

NASDAQ:ENGN

Biotechnology

Healthcare
$1.85 -1.15%

-$0.02 today

Market cap
$123.98M
Beta
-0.29
P/E (TTM)
-1.8
EPS (TTM)
-$0.95
52W Low $1.40High $12.25

Volume 2.81M

Average 1.58M

ENGN Other Income / Expenses

Net non-operating gains and losses, such as investment results, currency effects, and one-off items.

enGene Holdings Inc.NASDAQ: ENGN

Other Income / Expenses · Q2 FY2026 · quarter ended Apr 2026

Other income / expenses turns negative

Q2 FY2026 other income / expenses was -$1.74M, compared with $1.55M a year earlier. Trailing-twelve-month other income / expenses was $1.99M.

Context

  • Other income / expenses increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly other income / expenses holds near -$1.74M or moves back toward the trailing-twelve-month quarterly average of $497.75K.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterApr 2026
-$1.74M-221.5% QoQ
Last fiscal yearOct 2025
$5.86M-17.8% YoY
LTMApr 2026
$1.99M-76.1% YoY
Other Income / Expenses past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-212.4%——
1 year-17.8%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Other Income / Expenses history

USD · from the income statement

Latest · FY2025
5.86M USD
Year-over-year change
-17.8%

Other Income / Expenses vs competitors

How ENGN compares with its peers on the latest reported figures

  • Peers report in different currencies, so other income / expenses is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -76.1% is the 5th highest of 10, against a peer median of -79.4%.
ENGN Competitors
Other Income / Expenses for ENGN and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ANNXAnnexon, Inc.LTM Mar 2026$8.58M USD-44.7%+38.6%—
LRMRLarimar Therapeutics, Inc.LTM Mar 2026$6.42M USD-36.5%+80.0%—
ALTAltimmune, Inc.LTM Mar 2026$5.84M USD-19.7%+26.4%16213.9%
AMRNAmarin Corporation plcLTM Mar 2026$2.64M USD-79.4%—1.2%
ENGNenGene Holdings Inc.LTM Apr 2026$1.99M USD-76.1%——
DBVTDBV Technologies S.A.LTM Mar 2026$1.55M USD+54.4%+12.0%—
SLNSilence Therapeutics plcLTM Mar 2026$1.43M USD—-50.1%155.2%
ACIUAC Immune S.A.LTM Mar 2026-CHF 1.47M CHF-268.3%—39.8%
CLLSCellectis S.A.LTM Mar 2026-$23.45M USD-215.6%—34.4%
KRROKorro Bio, Inc.LTM Mar 2026-$30.01M USD-466.4%—781.1%
ANROAlto Neuroscience, Inc.LTM Mar 2026-$129.21M USD-2023.6%+28.2%—
Peer median (excluding ENGN) —-79.4%+27.3%97.5%

Competitors are the stored peer set for ENGN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Oct 2021
FY2022
Oct 2022
FY2023
Oct 2023
FY2024
Oct 2024
FY2025
Oct 2025
Revenue00000
Cost of Revenue00000
Gross Profit00000
Gross Margin—————
Research & Development12.46M15.47M16.46M38.32M94.48M
Selling, General & Admin3.16M3.26M8.47M23.98M28.69M
Operating Expenses15.87M19.43M26.06M62.3M123.17M
Depreciation & Amortization272K238K175K323K509K
EBITDA(18.15M)(22.78M)(94.77M)(52.04M)(113.8M)
EBITDA Margin—————
Operating Income(15.87M)(19.43M)(26.06M)(62.3M)(123.17M)
Operating Margin—————
Interest Income25K129K1.12M10.41M9.43M
Interest Expense5.02M1.42M4.95M2.8M2.99M
Other Income / Expenses(7.57M)(5.01M)(73.84M)7.14M5.86M
Income Before Tax(23.44M)(24.44M)(99.9M)(55.16M)(117.3M)
Pre-Tax Margin—————
Income Tax Expense022K17K(19K)0
Net Income(23.44M)(24.46M)(99.92M)(55.14M)(117.3M)
Net Margin—————
EPS (Basic)(0.01)0.00(4.24)(1.46)(2.29)
EPS (Diluted)(0.01)0.00(4.24)(1.46)(2.29)
Weighted Avg Shares15.81M15.81M23.56M44.64M51.12M
Weighted Avg Shares (Diluted)15.81M15.81M23.56M44.64M51.12M

enGene Holdings Inc.

NASDAQ:ENGN

Intrinsic Alpha fair value

Locked

Current Price

$1.85

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.